COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022.
Lindsey WangNathan A BergerPamela B DavisDavid C KaelberNora D VolkowRong XuPublished in: medRxiv : the preprint server for health sciences (2022)
COVID-19 rebound occurred both after Paxlovid and Molnupiravir, especially in patients with underlying medical conditions. This indicates that COVID-19 rebound is not unique to Paxlovid and the risks were similar for Paxlovid and Molnupiravir. For both drugs the rates of COVID-19 rebound increased with time after treatments. Our results call for continuous surveillance of COVID-19 rebound after Paxlovid and Molnupiravir treatments. Studies are necessary to determine the mechanisms underlying COVID-19 rebounds and to test dosing and duration regimes that might prevent such rebounds in vulnerable patients.